Community-associated methicillin-resistant Staphylococcus aureus: New bug, old drugs

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1125-1133

  Sabol, Kathryn E ^a   Echevarria, Kelly L ^b,c   Lewis II, James S ^c,d  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Community associated; Community acquired; Mec; Methicillin resistance; Panton Valentine leukocidin; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; GATIFLOXACIN; GEMIFLOXACIN; LEUKOCIDIN; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; PANTON VALENTINE LEUKOCIDIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STAPHYLOCOCCUS TOXIN; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COMMUNITY ASSOCIATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; DOUBLING TIME; DRUG DOSE REGIMEN; EMBASE; GENE CASSETTE; GENOTYPE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCAL CASSETTE CHROMOSOME MEC; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; GENOTYPE; HISTORY, 19TH CENTURY; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33745067510     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G404     Document Type: Review

References (84)

1. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002;359:1819-27.
2. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:400-7.
3. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998;26:1179-81.
4. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941;68:851-75.
5. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
6. Palavencino E. Community-acquired methicillin-resistant Staphylococcus aureus infections. Clin Lab Med 2004;24:403-18.
7. Barrett FF, McGehee RF, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med 1968;279:441-8.
8. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-10.
9. Begier EM, Frenette K, Barrett BL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004;39:1446-53.
10. Lindenmayer JM, Schoenfield S, O'Grady R, Carney JK. Methicillin- resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 1998;158:895-9.
11. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003;52:793-5.
12. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003;52:992-6.
13. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001;286:1201-5.
14. Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children. Pediatr Infect Dis J 2001;20:860-3.
15. Moreillon P, Que Y, Glauser MP. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier, 2004:2321-51.
16. Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002;186:1344-7.
17. Eady EA, Cove JS. Staphylococcal resistance revisited: community-acquired methicillin-resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24.
18. Charlebois ED, Perdreau-Remington F, Kreisworth B, et al. Origins of community strains of methicillin resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54.
19. Fridkin SK, Hagerman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
20. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84.
21. Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002;43:225-32.
22. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcal aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-8.
23. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-20.
24. Public health dispatch: outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003;52:88.
25. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006;367:705-6.
26. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-reisistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002;40:4289-94.
27. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-52.
28. Hiramatsu K, Okuma K, Ma X, Yamamoto M, Hori S, Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis 2002;15:407-13.
29. Ito T, Ma XX, Takeuchi F, Keiko O, Yuzaawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004;48:2637-51.
30. Tacconelli E, Venkataraman L, DeGirolami PC, D'Agata EMC. Methicillin-resistant Staphylococcus aureus bacteremia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare- associated strains. J Antimicrob Chemother 2004;53:474-9.
31. Rybak MJ, La Plante K. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005;25:74-85.
32. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932;1:506-8.
33. Lina G, Peimont Y, Godall-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32.
34. Gillet Y, Issartel B, Venhems P, et al. Association between Staphylococcus aureus strains carrying genes for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002;359:753-9.
35. Boubaker K, Diebold P, Blanc DS, et al. Panton-Valentine leukocidin and staphylococcal skin infections in schoolchildren. Emerg Infect Dis 2004;10:121-4.
36. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections carrying Panton-Valentine leukocidin: worldwide emergence. Emerg Infect Dis 2003;9:978-84.
37. DuFour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-24.
38. Diep BA, Sensabaugh GE, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leukocidin. J Clin Microbiol 2004;42:2080-4.
39. Bagget HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004;189:1565-73.
40. Ellis M, Hospenthal D, Dooley D, Gray P, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcal aureus infection in soldiers. Clin Infect Dis 2004;39:971-9.
41. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for treatment of Staphylococcal aureus infections. Ann Intern Med 1992;117:390-8.
42. Reese RE, Betts RF. Clindamycin. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts' a practical approach to infectious diseases. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2003:1077-80.
43. Package insert. Vibramycin (doxycycline). New York: Pfizer, September 2003.
44. Package insert. Minocin(minocycline). Philadelphia: Wyeth Pharmaceuticals, October 2005.
45. Package insert. Levaquin (levofloxacin). Raritan, NJ: Ortho-McNeil Pharmaceutical, August 2005.
46. Package insert. Tequin (gatifloxacin). Princeton, NJ: Bristol-Myers Squibb September 2005.
47. Package insert. Avelox (moxifloxacin). West Haven, CT: Bayer HealthCare, July 2005.
48. Package insert. Zyvox (linezolid). New York: Pfizer, November 2005.
49. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004;38:338-41. Epub 30 Dec 2003. DOI 10.1345/aph.1D156
50. Elwell LP, Wilson HR, Knick VB, Keith BR. In vitro and in vivo efficacy of the combination of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986;29:1092-4.
51. Hedstrom SA. Clindamycin as an anti-staphylococcal agent-indications and limitations. Scand J Infect Dis Suppl 1984;43:62-6.
52. Frank AL, Marcinak JF, Mangat PD, Schrekenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999;18:993-1000.
53. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40:280-5.
54. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards, 2004.
55. Qadri SMH, Halim M, Ueno Y, Saldin H. Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials. Chemotherapy 1994;40:26-9.
56. Lewis SA, Altemeier WA. Correlation of in vitro resistance of Staphylococcus aureus to tetracycline, doxycycline, and minocycline with in vivo use. Chemotherapy 1976;22:319-23.
57. Minuth JN, Holmes TN, Musher DM. Activity of tetracycline, doxycycline and minocycline against methicillin-susceptible and -resistant staphylococci. Antimicrob Agents Chemother 1974;6:411-4.
58. Yuk JH, Dignani MC, Harris RL, Bradshaw MW, Williams TW. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 1991;13:1023-4.
59. Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F. Combination of minocycline and rifampicin against methicillin-resistant and gentamicin-resistant Staphylococcus aureus. J Clin Pathol 1981;34:559-63.
60. Segretti J, Gvazdinskas LC, Trenholme GM. In vitro activity of minocycline and rifampin against staphylococci. Diagn Microbiol Infect Dis 1989;12:253-5.
61. Clumeck N, Marcelis L, Amiri-Iamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984;13(suppl C):17-22.
62. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005;40:1429-34.
63. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol 1989;27:335-6.
64. Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis 1991;163:1080-6.
65. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Emergence of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-85.
66. Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance to nosocomial methicillin-resistant Staphylococcus aureus isolates. Arch Intern Med 1990;50:2151-5.
67. Presterl E, Mueller-Uri P, Grisold A, Georgopoulos A, Graninger W. Ciprofloxacin- and methicillin-resistant Staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Eur J Clin Microbiol Infect Dis 2001;20:486-9.
68. Stein GE, Schooley S, Kaatz GW. Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high? Clin Infect Dis 2003;37:1392-5.
69. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. Wayne, PA: NCCLS, 2005.
70. Jones ME, Boenik NM, Verhoef J, Kohrer K, Schmitz F. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment. J Antimicrob Chemother 2000;45:353-6.
71. Shopsin B, Zhao X, Kreisworth BN, Tillotson GS, Drlica K. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004;24:32-4.
72. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmell Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2002;9:1415-22.
73. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
74. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, for the Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
75. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
76. Frippiat F, Bergiers C, Michel C, Dujardin J, Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004;53:1114-5.
77. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multi-drug resistant, gram-positive infections: experiences from a compassionate use program. Clin Infect Dis 2003;36:159-68.
78. Package insert. Synercid (quinupristin/dalfopristin). Bristol, TN: Monarch Pharmaceuticals, July 2003.
79. Package insert. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, September 2003.
80. Package insert. Tygacil (tigeocycline). Philadelphia: Wyeth Pharmaceuticals, June 2005.
81. Perdreau-Remington F, Carleton HA, Etrorma J, Diep BA, Sensabaugh GF. Alarming prevalence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in hospitalized patients (abstract K-1859-a). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
82. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17.
83. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-56.
84. Hidron AI, Kaurbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005;41:159-66.